Evidence map›Paper›PMID 34272327›Full record

Trial reportJournal of the American Society of Nephrology : JASN2021

Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.

Glenn M Chertow, Priya Vart, Niels Jongs, Robert D Toto, Jose Luis Gorriz, Fan Fan Hou, John J V McMurray, Ricardo Correa-Rotter, Peter Rossing, C David Sjöström and 5 more

2 registry-linked trialsOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Society of Nephrology : JASN, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 111 papers, 17 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
111citing papers in PubMed, 17 pooled it
20.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05374291 phase3enrolling by invitationstarted 2022, after this paper: background citation

A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe Chronic Kidney Disease

Ran2022Enrolled1,750Registered outcomes12Posted comparisons0ConditionsDeath, Heart Failure, Kidney Disease, Chronic, Kidney FailureArmsDapagliflozin 10 mg/day (oral), Placebo
PMID 30990260PMID 40053493PMID 34619108PMID 33213078other papers from this trial
Open the trial in the graph
NCT06982079 phase3recruitingnot on this mapstarted 2025, after this paper: background citation

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease

TypeinterventionalSponsorAin Shams UniversityRan2025 to 2026Enrolled60ConditionsChronic Kidney Disease Stage 5, CKD Stage 4ArmsDapagliflozin 10 mg
3 · Its place in the literature

Who cites it

111 citing papers in PubMed, 17 syntheses or guidelines pooled it, 190 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Trial
  19. Trial
  20. Review

51 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 9 countries.

Glenn M ChertowDepartments of Medicine and Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California.
Priya VartDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
Niels JongsDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
Robert D TotoDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0001-9531-1749
Jose Luis GorrizHospital Clinico Universitario de Valencia, University of Valencia, Valencia, Spain.
Fan Fan HouDivision of Nephrology, Nanfang Hospital, Southern Medical University, National Clinical Research Center for Kidney Disease, Guangzhou, China.
John J V McMurrayInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.
Ricardo Correa-RotterNational Medical Science and Nutrition Institute Salvador Zubirán, Mexico City, Mexico.
Peter RossingSteno Diabetes Center Copenhagen, Gentofte, Denmark.
C David SjöströmLate-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Bergur V StefánssonLate-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.ORCID 0000-0002-0777-5373
Anna Maria LangkildeLate-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
David C WheelerDepartment of Renal Medicine, University College London, United Kingdom.
Hiddo J L HeerspinkDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
DAPA-CKD Trial Committees and Investigators
AstraZeneca (Sweden) · SEUniversity Medical Center Groningen · NLInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXNanfang Hospital · CNStanford University · USThe George Institute for Global Health · AUThe University of Texas Southwestern Medical Center · USUniversitat de València · ESUniversity of Copenhagen · DKUniversity of Glasgow · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized, placebo-controlled trial, the sodium-glucose cotransporter 2 inhibitor dapagliflozin significantly reduced risk of kidney failure and prolonged survival in patients with CKD with or without type 2 diabetes.

methodsAdults with eGFR of 25-75 ml/min per 1.73 m

resultsA total of 293 participants with stage 4 CKD received dapagliflozin and 331 received placebo. Patients with stage 4 CKD randomized to dapagliflozin experienced a 27% (95% confidence interval [95% CI]: -2 to 47%) reduction in the primary composite endpoint, and 29% (-2 to 51%), 17% (-53 to 55%), and 32% (-21 to 61%) reductions in the kidney, cardiovascular and mortality endpoints, respectively, relative to placebo. Interaction P-values were 0.22, 0.13, 0.63, and 0.95, respectively, comparing CKD stages 4 versus 2/3. The eGFR slope declined by 2.15 and 3.38 ml/min per 1.73 m

conclusionsAmong patients with stage 4 CKD and albuminuria, the effects of dapagliflozin were consistent with those observed in the DAPA-CKD trial overall, with no evidence of increased risks.

Indexed as

AgedBenzhydryl CompoundsCardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic NephropathiesFemaleGlomerular Filtration RateGlucosidesHumansMaleMiddle AgedRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsdapagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitorschronic kidney diseasedapagliflozinSGLT2 inhibitorstage 4 CKD

Identifiers

PMID34272327
PMCPMC8729835
OpenAlexW3179094902

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.